Opexa Therapeutics to Present at September Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Opexa Therapeutics (OPXA) Enters $5M Common Stock Purchase Agreement
September 1, 2015 6:23 AM EDTOpexa Therapeutics (NASDAQ: OPXA) announced that the Company has entered into a stock purchase agreement with a private investor to fund the Companys NMO program, including its planned Phase I/II trial, for up to $5 million, upon achievement of certain pre-specified milestones.
The funding is to be provided in five tranches, based on the successful completion of milestones, with the first tranche having been delivered today, the effective date of this agreement. For the first tranche, the company issued shares priced at $0.55 per share for a purchase amount of $500,000. The total... More
